Warning letter
Biomedical Research Institute of America d/b/a BioMed IRB: warning letter of Mar 29, 2012
FDA warning letter 278719 · Center for Biologics Evaluation and Research
Key facts
| Reference number | 278719 |
|---|---|
| Company | Biomedical Research Institute of America d/b/a BioMed IRB |
| Subject | Institutional Review Board (IRB) |
| Issue date | Mar 29, 2012 |
| Posted date | Mar 29, 2012 |
| Issuing office | Center for Biologics Evaluation and Research |
| Product type | Biologics |
| CFR sections cited | 56.107(f), 56.108(c), 56.115(a)(2), 56, 56.107, 56.111 |
| Inspection city | San Diego |
| Inspection ZIP | 92108 |
| Inspection start date | Aug 8, 2011 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: